Filing Flows › Neogenomics (NEO) › Q3 2026 › vs Q3 2025
Neogenomics (NEO) Q3 2026 vs Q3 2025 (year over year)
Neogenomics's revenue rose $21.5M (+11%) from $188M in Q3 2025 to $209M in Q3 2026. The biggest changes: Commercial insurance +$12.2M (+38%); Medicare and other government +$6.0M (+26%); Client direct billing +$3.3M (+2%).
Neogenomics, Q3 2026: revenue $209M (+11% year over year), operating margin -3.8%, net loss $7.5M, operating cash flow −$8.9M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Client direct billing | $136M | $132M | $3.3M | +2% |
| Commercial insurance | $44.7M | $32.5M | $12.2M | +38% |
| Medicare and other government | $29.0M | $23.0M | $6.0M | +26% |
| Revenue | $209M | $188M | $21.5M | +11% |
| Income tax benefit | $475K | −$740K | $1.2M | — |
| Net loss | $7.5M | $27.1M | −$19.6M | -72% |
| Costs & expenses | $217M | $216M | $1.7M | +0.8% |
| Operating costs | $217M | $215M | $2.4M | +1% |
| Cost of revenue | $113M | $107M | $5.3M | +5% |
| Research & development | $9.9M | $8.7M | $1.2M | +13% |
| Sales & marketing | $27.6M | $21.8M | $5.8M | +27% |
| General & admin | $67.1M | $69.9M | −$2.8M | -4% |
| Operating cash sources | $33.9M | $17.9M | $16.1M | +90% |
| Depreciation & amortization | $16.2M | $16.4M | −$248K | -2% |
| Share-based compensation | $8.8M | $10.3M | −$1.5M | -14% |
| Cash used in operations | $8.9M | −$8.9M | $17.8M | — |
| Net loss absorbed | $7.5M | $27.1M | −$19.6M | -72% |
| Working capital & other | $26.4M | −$9.3M | $35.6M | — |
Questions
How much did Neogenomics's revenue grow year over year in Q3 2026?
Neogenomics's revenue rose $21.5M (+11%) from $188M in Q3 2025 to $209M in Q3 2026.
What drove Neogenomics's revenue change in Q3 2026?
Commercial insurance +$12.2M (+38%); Medicare and other government +$6.0M (+26%); Client direct billing +$3.3M (+2%).